Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Clinical and biochemical characteristics of patients treated with teriparatideTeriparatide group (n = 39)At start of treatmentEnd of treatmentOsteoporosis risk factors, n (%)Diabetes mellitusMenopauseMale hypogonadismSmokingBMI, kg/m215 (38%)22 (85%)5 (38%)1 (3%)25.0 ± 4.2Hypoparathyroidism, n (%)3 (8%)Calcium supplement, n (%)31 (79%)Vitamin D supplement, n (%)37 (95%)Fragility fractures, n (%)Prior fractures (before teriparatide therapy)35 (90%)Incident fractures (after the initiation of teriparatide)6 (17%)BMD T score ≤ (−2.5), n (%)Lumbar spineFemoral neckTotal hip17/33 (52%)22/36 (61%)12/19 (63%)6/20 (30%)9/22 (41%)8/18 (44%)Corrected calcium (mg/dL)Phosphorus (mg/dL)Vitamin D (nmol/L)Uric acid (mg/dL)Urine calcium (mg/day)9.1 ± 1.13.8 ± 0.666.8 ± 23.25.6 ± 1.5124.0 ± 91.49.3 ± 1.23.3 ± 0.776.3 ± 24.96.5 ± 1.398.6 ± 55.4BMD bone mineral density, ND not available/not systematically collected

Source: Teriparatide exposure. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

We conducted a retrospective cohort study at a large transplant center including adult kidney, lung, and liver transplant recipients selected for teriparatide treatment based on clinical indications for severe post-transplant osteoporosis for at least 3 months.

Source: Abstract.

Patients were followed from initiation of teriparatide therapy until treatment discontinuation and subsequent clinical follow-up, when available.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Teriparatide treatment of osteoporosis in solid organ transplant recipients: a single-center experience

Cohort study · Archives of Osteoporosis · 2026

Original publication title

Teriparatide treatment of osteoporosis in solid organ transplant recipients: a single-center experience

Talia Diker Cohen; Ilana Shraga-Slutzky; Keren Kaminer; Alexander Gorshtein; Idit Dotan; Gloria Tsvetov

© The Author(s) 2026

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

In this real-world cohort of SOT recipients with severe osteoporosis, teriparatide therapy was associated with significant improvements in BMD, acceptable safety, and no apparent excess risk to graft function. These findings support the selective use of anabolic therapy in high-risk transplant recipients and highlight the need for prospective studies to define optimal treatment strategies.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

Solid organ transplant (SOT) recipients are at high risk for osteoporosis and fragility fractures due to pre-existing organ dysfunction and long-term immunosuppressive therapy, particularly glucocorticoids. However, evidence supporting the use of anabolic osteoporosis therapy in this population remains limited.

Source: Purpose

Abstract: What methods does the paper describe?

We conducted a retrospective cohort study at a large transplant center including adult kidney, lung, and liver transplant recipients selected for teriparatide treatment based on clinical indications for severe post-transplant osteoporosis for at least 3 months. Bone mineral density (BMD), incident fractures, biochemical parameters, renal function, and adverse events were evaluated during treatment and follow-up.

Source: Methods

Abstract: Summary

Solid organ transplant recipients face high fracture risk with limited evidence guiding anabolic therapy. In this real-world cohort, teriparatide was associated with significant improvements in bone mineral density and acceptable safety without adverse graft effects. These findings support selective anabolic treatment in high-risk transplant recipients and highlight the need for prospective studies.

Source: Summary

Abstract: Results

Thirty-nine SOT recipients (33% men; mean age 61.3 ± 11.6 years) were included, comprising kidney (n = 10), lung (n = 20), and liver (n = 9) transplant recipients. Prior fragility fractures were present in 90% of patients, and 79% had multiple fractures. Median teriparatide treatment duration was 22.3 months. Significant increases in BMD were observed at the lumbar spine (+11 ± 15%, p = 0.01), femoral neck (+8 ± 14%, p = 0.05), and total hip (+11 ± 16%, p = 0.05).

Six patients sustained fractures after teriparatide initiation; only two occurred during active therapy, whereas four occurred after treatment discontinuation. Hypercalcemia occurred in one patient and led to treatment cessation. The estimated glomerular filtration rate declined modestly during the first 6 months and stabilized thereafter; a broadly similar pattern was observed in contemporaneous matched transplant controls. No episodes of graft rejection were observed.

Source: Results

Abstract: Conclusions

In this real-world cohort of SOT recipients with severe osteoporosis, teriparatide therapy was associated with significant improvements in BMD, acceptable safety, and no apparent excess risk to graft function. These findings support the selective use of anabolic therapy in high-risk transplant recipients and highlight the need for prospective studies to define optimal treatment strategies.

Source: Conclusions
Authors’ abstract

Summary

Solid organ transplant recipients face high fracture risk with limited evidence guiding anabolic therapy. In this real-world cohort, teriparatide was associated with significant improvements in bone mineral density and acceptable safety without adverse graft effects. These findings support selective anabolic treatment in high-risk transplant recipients and highlight the need for prospective studies.

Purpose

Solid organ transplant (SOT) recipients are at high risk for osteoporosis and fragility fractures due to pre-existing organ dysfunction and long-term immunosuppressive therapy, particularly glucocorticoids. However, evidence supporting the use of anabolic osteoporosis therapy in this population remains limited.

Methods

We conducted a retrospective cohort study at a large transplant center including adult kidney, lung, and liver transplant recipients selected for teriparatide treatment based on clinical indications for severe post-transplant osteoporosis for at least 3 months. Bone mineral density (BMD), incident fractures, biochemical parameters, renal function, and adverse events were evaluated during treatment and follow-up.

Results

Thirty-nine SOT recipients (33% men; mean age 61.3 ± 11.6 years) were included, comprising kidney (n = 10), lung (n = 20), and liver (n = 9) transplant recipients. Prior fragility fractures were present in 90% of patients, and 79% had multiple fractures. Median teriparatide treatment duration was 22.3 months. Significant increases in BMD were observed at the lumbar spine (+11 ± 15%, p = 0.01), femoral neck (+8 ± 14%, p = 0.05), and total hip (+11 ± 16%, p = 0.05).

Six patients sustained fractures after teriparatide initiation; only two occurred during active therapy, whereas four occurred after treatment discontinuation. Hypercalcemia occurred in one patient and led to treatment cessation. The estimated glomerular filtration rate declined modestly during the first 6 months and stabilized thereafter; a broadly similar pattern was observed in contemporaneous matched transplant controls. No episodes of graft rejection were observed.

Conclusions

In this real-world cohort of SOT recipients with severe osteoporosis, teriparatide therapy was associated with significant improvements in BMD, acceptable safety, and no apparent excess risk to graft function. These findings support the selective use of anabolic therapy in high-risk transplant recipients and highlight the need for prospective studies to define optimal treatment strategies.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1007/s11657-026-01751-4.

Publication and source details

Original title: Teriparatide treatment of osteoporosis in solid organ transplant recipients: a single-center experience

Talia Diker Cohen; Ilana Shraga-Slutzky; Keren Kaminer; Alexander Gorshtein; Idit Dotan; Gloria Tsvetov

Archives of Osteoporosis · 2026

© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Tel Aviv University

Open access funding provided by Tel Aviv University.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T21:45:14.876882+00:00

DOI: 10.1007/s11657-026-01751-4 · PMC13538171